367 related articles for article (PubMed ID: 32708810)
61. Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
Sokolova A; Johnstone KJ; McCart Reed AE; Simpson PT; Lakhani SR
Histopathology; 2023 Jan; 82(1):70-82. PubMed ID: 36468211
[TBL] [Abstract][Full Text] [Related]
62. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract][Full Text] [Related]
63. Utility of germline multi-gene panel testing in patients with endometrial cancer.
Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
[TBL] [Abstract][Full Text] [Related]
64. Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
Loveday C; Garrett A; Law P; Hanks S; Poyastro-Pearson E; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Walker L; ; Eccles D; Evans DG; Snape K; Hanson H; Houlston RS; Turnbull C
Ann Oncol; 2022 Dec; 33(12):1318-1327. PubMed ID: 36122798
[TBL] [Abstract][Full Text] [Related]
65. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
66. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Pearlman R; Frankel WL; Swanson B; Zhao W; Yilmaz A; Miller K; Bacher J; Bigley C; Nelsen L; Goodfellow PJ; Goldberg RM; Paskett E; Shields PG; Freudenheim JL; Stanich PP; Lattimer I; Arnold M; Liyanarachchi S; Kalady M; Heald B; Greenwood C; Paquette I; Prues M; Draper DJ; Lindeman C; Kuebler JP; Reynolds K; Brell JM; Shaper AA; Mahesh S; Buie N; Weeman K; Shine K; Haut M; Edwards J; Bastola S; Wickham K; Khanduja KS; Zacks R; Pritchard CC; Shirts BH; Jacobson A; Allen B; de la Chapelle A; Hampel H;
JAMA Oncol; 2017 Apr; 3(4):464-471. PubMed ID: 27978560
[TBL] [Abstract][Full Text] [Related]
67. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.
Cheng HH; Klemfuss N; Montgomery B; Higano CS; Schweizer MT; Mostaghel EA; McFerrin LG; Yu EY; Nelson PS; Pritchard CC
Prostate; 2016 Oct; 76(14):1303-11. PubMed ID: 27324988
[TBL] [Abstract][Full Text] [Related]
68. A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
Kerr L; Rewhorn MJ; Longmuir M; Fraser S; Walsh S; Andrew N; Leung HY
BMC Cancer; 2016 Jul; 16():529. PubMed ID: 27456091
[TBL] [Abstract][Full Text] [Related]
69. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
[TBL] [Abstract][Full Text] [Related]
70. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer.
Rantapero T; Wahlfors T; Kähler A; Hultman C; Lindberg J; Tammela TL; Nykter M; Schleutker J; Wiklund F
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183364
[TBL] [Abstract][Full Text] [Related]
71. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
72. Germline Predisposition to Prostate Cancer in Diverse Populations.
Bree KK; Hensley PJ; Pettaway CA
Urol Clin North Am; 2021 Aug; 48(3):411-423. PubMed ID: 34210495
[TBL] [Abstract][Full Text] [Related]
73. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
74. Association of rare MSH6 variants with familial breast cancer.
Wasielewski M; Riaz M; Vermeulen J; van den Ouweland A; Labrijn-Marks I; Olmer R; van der Spaa L; Klijn JG; Meijers-Heijboer H; Dooijes D; Schutte M
Breast Cancer Res Treat; 2010 Sep; 123(2):315-20. PubMed ID: 19924528
[TBL] [Abstract][Full Text] [Related]
75. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
[TBL] [Abstract][Full Text] [Related]
76. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
77. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
Brook MN; Ní Raghallaigh H; Govindasami K; Dadaev T; Rageevakumar R; Keating D; Hussain N; Osborne A; Lophatananon A; ; Muir KR; Kote-Jarai Z; Eeles RA
Eur Urol; 2023 Mar; 83(3):257-266. PubMed ID: 36528478
[TBL] [Abstract][Full Text] [Related]
78. The spectrum of mutations predisposing to familial breast cancer in Poland.
Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Rusak B; Stempa K; Gronwald J; Szymiczek A; Bagherzadeh M; Jakubowska A; Dębniak T; Lener M; Rudnicka H; Szwiec M; Jarkiewicz-Tretyn J; Stawicka M; Domagała P; Narod SA; Lubiński J; Akbari MR;
Int J Cancer; 2019 Dec; 145(12):3311-3320. PubMed ID: 31173646
[TBL] [Abstract][Full Text] [Related]
79. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
80. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
